Skip to main content

Treatment Clinical Trials for Pancreatic Cancer

Review the pancreatic cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 210

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Surgical Resection after Chemotherapy for the Treatment of Pulmonary or Hepatic Oligometastatic Pancreatic Cancer
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Status: Active
Location: See ClinicalTrials.gov
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Status: Active
Location: See ClinicalTrials.gov
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Status: Active
Location: See ClinicalTrials.gov
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Status: Active
Location: See ClinicalTrials.gov
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Status: Active
Location: See ClinicalTrials.gov
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Status: Active
Location: University of California San Francisco, San Francisco, California
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Status: Active
Location: See ClinicalTrials.gov
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Status: Active
Location: See ClinicalTrials.gov
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: University of Colorado, Denver, Colorado
Stereotactic Body Radiotherapy with or without Defactinib plus Avutometinib for the Treatment of Advanced Pancreatic Adenocarcinoma after Standard of Care Induction Chemotherapy
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Status: Temporarily Closed to Accrual
Location: University of Nebraska Medical Center, Omaha, Nebraska
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland